Chronic autoimmune inflammatory skin disease characterized by T cell-mediated hyperactivation (particularly Th1/Th17 subsets), excessive keratinocyte proliferation with a cell turnover of 3-5 days (versus normal 28 days), and systemic low-grade inflammation. Represents a prototypical example of barrier dysfunction meeting immune dysregulation, where psychological stress, metabolic disturbance, and microbial triggers converge through the IL-23/IL-17 axis to drive persistent tissue inflammation and abnormal epidermal differentiation.
Imagine a construction site where the building crew (keratinocytes) normally takes four weeks to complete one floor, following a careful blueprint. In psoriasis, an overzealous foreman (Th17 cells) stands at the site with a megaphone blasting IL-17 commands, demanding the crew build a new floor every 3-5 days. The workers race to comply, but the rushed construction produces malformed, incomplete floors that pile up as thick, scaly plaques. The foreman himself was hired by a corrupt manager (IL-23 from dendritic cells) who keeps sending more foremen to the site. Meanwhile, the fire department (TNF-α and IL-1β) keeps arriving even though there's no fire, spraying inflammatory foam everywhere. The site supervisor (regulatory T cells) tries to call everyone off, but their walkie-talkie batteries are dead—they've lost the ability to suppress the chaos. To make matters worse, the site's general contractor (the autonomic nervous system) is sleep-deprived and stress-reactive, randomly activating emergency construction protocols through sympathetic surges, ensuring the chaos never stops. The entire neighborhood (systemic circulation) now has inflammatory debris floating down the street, affecting distant buildings (cardiovascular system, joints).
Psoriasis pathogenesis involves a complex cascade initiated at the interface of innate and adaptive immunity:
Initiation Phase:
- Trauma, infection (Streptococcus), or psychological stress triggers keratinocyte production of antimicrobial peptides (LL-37, β-defensin-2)
- LL-37 complexes with self-DNA/RNA → activates plasmacytoid dendritic cells via TLR7/TLR9
- Activated DCs migrate to lymph nodes, produce IL-12 and IL-23
- Mast cells and neutrophils release additional IL-1β, IL-6, and TNF-α
T Cell Polarization:
- IL-12 drives naive T cells → Th1 (producing IFN-γ, TNF-α)
- IL-23 (p19/p40 heterodimer) binds IL-23R on T cells → drives Th17 differentiation via STAT3 activation
- Th17 cells produce IL-17A, IL-17F, IL-22, and IL-26
- IL-23 also maintains Th17 memory, ensuring chronicity
Keratinocyte Amplification Loop:
graph TD
A[IL-17A/F bind IL-17RA/RC] --> B[Activates Act1 adaptor protein]
B --> C["NF-κB and C/EBP activation"]
C --> D[Keratinocyte gene expression]
D --> E1["Antimicrobial peptides: LL-37, S100A7/8/9"]
D --> E2["Chemokines: CXCL1, CXCL2, CCL20"]
D --> E3["Cytokines: IL-1β, IL-6, IL-8"]
D --> E4["Proliferation genes: Ki67+"]
E2 --> F[Recruit neutrophils and more Th17]
E3 --> G[Amplify inflammation]
F --> A
G --> A
Keratinocyte Hyperproliferation Mechanism:
- IL-22 binds IL-22R1/IL-10R2 → JAK1/TYK2 → STAT3 activation
- STAT3 upregulates genes: cyclin D1, c-Myc, survivin
- Cell cycle time reduced from 28 days to 3-5 days
- Abnormal differentiation: parakeratosis (retained nuclei in stratum corneum), loss of granular layer
Neuro-Immune Interface:
- Chronic psychological stress → HPA axis activation → cortisol release
- Paradoxically, keratinocytes and T cells develop glucocorticoid receptor resistance through:
- FKBP5 upregulation (competes for GR binding)
- SOCS1/3 induction (inhibits cortisol signaling)
- Pro-inflammatory NFκB sequestering GR in cytoplasm
- Sympathetic activation → norepinephrine release → β2-adrenergic signaling on immune cells
- Norepinephrine enhances IL-17 production via cAMP/PKA pathway
- Substance P and CGRP from sensory neurons directly activate mast cells and amplify inflammation
Systemic Consequences:
- Chronic IL-17, TNF-α, IL-6 spillover → hepatic acute phase response (CRP >3 mg/L common)
- IL-6 → insulin resistance via SOCS3 induction in hepatocytes and adipocytes
- TNF-α → endothelial dysfunction, increased VCAM-1/ICAM-1 → accelerated atherosclerosis
- Systemic inflammation → 40-50% develop metabolic syndrome within 10 years
Psoriasis serves as the archetypal teaching model in cPNI for several reasons:
Metamodel Integration:
- Metamodel 0 (Evolutionary Mismatch): The Th17/IL-23 axis evolved as anti-fungal and anti-bacterial barrier defense; chronic activation without resolution represents mismatch between ancestral pathogen load and modern sterile inflammation triggers
- Metamodel 1 (Chronic Stress): Demonstrates stress axis desynchronization—cortisol resistance means the HPA axis signal is present but tissue response is absent, creating a "disconnected fire alarm"
- Metamodel 3 (Barrier Dysfunction): Skin barrier failure (loss of filaggrin, aberrant tight junctions) both initiates and perpetuates the disease
- Metamodel 5 (Unresolved Inflammation): Profound deficiency in specialized pro-resolving mediators (RvD1, RvE1, LXA4)—patients have elevated LOX-5 activity but impaired LOX-12/15, blocking the lipid mediator class switch
Clinical Thresholds:
- Psoriasis Area and Severity Index (PASI) >10 = moderate-to-severe disease
- CRP often 5-15 mg/L (vs. <1 mg/L in healthy controls)
- IL-17A serum levels 10-50 pg/mL (vs. undetectable in controls)
- 30% develop psoriatic arthritis (inflammatory joint disease)
- 2-3× increased risk of myocardial infarction (driven by chronic IL-6, TNF-α)
- 50-60% have metabolic syndrome comorbidity
Intervention Implications:
- Anti-inflammatory diet: Omega-3 (EPA 2-3g/day) provides substrate for SPM synthesis; reduces arachidonic acid-derived PGE2/LTB4
- Stress management: Meditation, breathwork to reduce sympathetic tone and restore GR sensitivity
- Gut barrier repair: 40% have gut dysbiosis (low Faecalibacterium prausnitzii, high Escherichia); probiotics and fiber restore SCFA production
- Vitamin D (50-100 IU/kg daily): Binds VDR on keratinocytes and T cells → inhibits Th17 differentiation, promotes Treg function
- Photobiomodulation/controlled UV: UVB (311 nm) induces keratinocyte apoptosis, reduces IL-23/IL-17
- Biologics as proof-of-concept: Anti-IL-17 (secukinumab, ixekizumab) achieve PASI 90 in 60-70% of patients, validating pathway centrality
- Cold exposure/heat therapy: Intermittent thermal stress improves autonomic balance, reduces inflammatory priming
Exam-Relevant Clinical Pearl:
Psoriasis patients who fail to respond to lifestyle interventions often have unrecognized oral dysbiosis (Porphyromonas gingivalis) or SIBO—address these barriers first before escalating to systemic immunosuppression.
- Keratinocyte turnover accelerates from 28 days to 3-5 days due to IL-22/STAT3 hyperactivation
- Th17 cells are the primary pathogenic subset, driven by IL-23 from activated dendritic cells
- IL-17A (homodimer) has higher potency than IL-17F; both signal through IL-17RA/RC heterodimer
- 30% of patients have positive family history (HLA-Cw6 is strongest genetic risk factor)
- Psychological stress triggers flares in 40-80% of patients via sympathetic and HPA axis activation
- Glucocorticoid resistance develops through FKBP5 upregulation and NFκB sequestration of GR
- Serum IL-6 >10 pg/mL correlates with metabolic syndrome presence and cardiovascular risk
- Omega-3 index <4% predicts poor SPM production and treatment resistance
- Anti-TNF biologics (infliximab) achieve 50% improvement in 60-70% but only address one cytokine
- 50% have gut dysbiosis with reduced butyrate-producing bacteria (Faecalibacterium, Roseburia)
- Vitamin D <30 ng/mL (75 nmol/L) impairs Treg differentiation and exacerbates Th17 responses
- Streptococcal pharyngitis is classic trigger for guttate psoriasis via molecular mimicry (M protein)
- Th17 — primary pathogenic T cell subset producing IL-17A/F, driven by IL-23 signaling
- IL-17 — central effector cytokine binding IL-17RA/RC to drive keratinocyte hyperproliferation and neutrophil chemotaxis
- IL-23 — heterodimeric cytokine (p19/p40) from dendritic cells that initiates and maintains Th17 polarization via STAT3
- TNF-α — pleiotropic inflammatory cytokine amplifying NF-κB activation in keratinocytes and endothelium; target of biologic therapy
- IL-6 — drives systemic acute phase response, insulin resistance via SOCS3, and contributes to Th17 differentiation
- keratinocyte — hyperproliferative epidermal cells responding to IL-17/IL-22 by producing antimicrobial peptides and chemokines, creating amplification loop
- NF-κB — master transcription factor activated by IL-17, TNF-α, and IL-1β driving inflammatory gene expression in keratinocytes
- T cell — adaptive immune cells with Th1/Th17 skewing central to disease; Treg dysfunction allows unrestrained inflammation
- cortisol resistance — glucocorticoid receptor dysfunction in psoriatic lesions due to chronic stress, preventing anti-inflammatory cortisol effects
- psychological stress — activates HPA axis and sympathetic nervous system, directly worsening psoriasis through catecholamine-driven Th17 enhancement
- HPA axis — stress axis showing desynchronization in psoriasis—cortisol elevated but tissue resistance prevents therapeutic effect
- sympathetic nervous system — norepinephrine release enhances IL-17 production via β2-adrenergic/cAMP pathway on T cells
- gut dysbiosis — 40-50% of patients show reduced Faecalibacterium prausnitzii and elevated Escherichia, contributing to systemic LPS and inflammation
- Specialized pro-resolving mediators (SPMs) — profound deficiency (especially RvD1, LXA4) due to impaired 12/15-LOX and omega-3 substrate depletion
- omega-3 fatty acids — EPA/DHA substrate for SPM synthesis; supplementation (2-3g/day) reduces PASI scores by 20-30%
- vitamin D — binds VDR on T cells to suppress IL-17, enhance Treg differentiation; deficiency (<30 ng/mL) worsens disease
- metabolic syndrome — present in 50-60% of psoriasis patients, driven by chronic IL-6/TNF-α causing insulin resistance and visceral adiposity
- low-grade inflammation — systemic CRP elevation (5-15 mg/L) reflecting IL-6/TNF spillover, accelerating atherosclerosis
- autoimmune disease — classified as T cell-mediated autoimmune condition with loss of tolerance to self-antigens presented by stressed keratinocytes
- inflammation — unresolved chronic inflammatory state in skin and systemically, driven by IL-23/IL-17 axis without counter-regulatory SPMs
- lifestyle interventions — omega-3, stress reduction, gut repair, vitamin D optimization can reduce PASI by 30-50% in compliant patients
- Streptococcus — pharyngeal infection classic trigger for guttate psoriasis via molecular mimicry between streptococcal M protein and keratinocyte antigens
- Clinical PNI — psoriasis used as teaching model demonstrating immune-neuro-metabolic integration and lifestyle intervention efficacy
- NLRP3 inflammasome — activated in psoriatic keratinocytes and dendritic cells, producing IL-1β that amplifies Th17 responses
- insulin resistance — develops in 40% due to chronic IL-6/TNF-α signaling through SOCS3 in liver and adipose tissue
- Faecalibacterium prausnitzii — butyrate-producing commensal reduced in psoriasis patients; depletion impairs gut barrier and Treg induction
- antimicrobial peptides — LL-37, S100A7/8/9 produced by hyperactive keratinocytes; LL-37 complexes with self-DNA to activate dendritic cells via TLR9
- Module 1 — Introduction to cPNI principles and psoriasis as model disease
- Module 5 — Specialized pro-resolving mediators and resolution deficits in psoriasis